IL189617A - Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors - Google Patents
Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptorsInfo
- Publication number
- IL189617A IL189617A IL189617A IL18961708A IL189617A IL 189617 A IL189617 A IL 189617A IL 189617 A IL189617 A IL 189617A IL 18961708 A IL18961708 A IL 18961708A IL 189617 A IL189617 A IL 189617A
- Authority
- IL
- Israel
- Prior art keywords
- quinolin
- dihydro
- dimethyl
- ylethynyl
- phenylethynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2005/003285 WO2007023242A1 (en) | 2005-08-24 | 2005-08-24 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
PCT/GB2006/003170 WO2007023290A1 (en) | 2005-08-24 | 2006-08-24 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
IL189617A0 IL189617A0 (en) | 2008-06-05 |
IL189617A true IL189617A (en) | 2012-08-30 |
Family
ID=36273537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL189617A IL189617A (en) | 2005-08-24 | 2008-02-19 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1931635A1 (es) |
JP (1) | JP2009506018A (es) |
KR (1) | KR20080031972A (es) |
CN (1) | CN101223142A (es) |
AR (1) | AR056044A1 (es) |
AU (1) | AU2006283359B2 (es) |
BR (1) | BRPI0615059A2 (es) |
CA (1) | CA2610873C (es) |
EA (1) | EA200800660A1 (es) |
IL (1) | IL189617A (es) |
MX (1) | MX2008001871A (es) |
NO (1) | NO20081428L (es) |
TW (1) | TWI329635B (es) |
WO (2) | WO2007023242A1 (es) |
ZA (1) | ZA200710668B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
SG181715A1 (en) * | 2009-12-18 | 2012-07-30 | Janssen Pharmaceutica Nv | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
JP5763672B2 (ja) * | 2009-12-18 | 2015-08-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | mGluR5受容体のアロステリック調節因子としての二環式チアゾール |
AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
WO2012052451A1 (en) | 2010-10-18 | 2012-04-26 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
WO2012139876A1 (en) | 2011-04-14 | 2012-10-18 | Merz Pharma Gmbh & Co. Kgaa | Enteric formulations of metabotropic glutamate receptor modulators |
WO2012172093A1 (en) * | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dihydroindolizine derivate as metabotropic glutamate receptor modulators |
WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
EP2650284A1 (en) * | 2012-04-10 | 2013-10-16 | Merz Pharma GmbH & Co. KGaA | Heterocyclic derivatives as metabotropic glutamate receptor modulators |
KR101418078B1 (ko) * | 2013-01-23 | 2014-07-10 | 한국과학기술연구원 | mGluR5 길항제로서의 2-(치환된에티닐)퀴놀린 유도체 |
MX2016006325A (es) | 2013-11-15 | 2016-12-02 | Wistar Inst | Inhibidores del antígeno nuclear 1 de epstein-barr, y su método de uso. |
KR101579496B1 (ko) * | 2014-07-03 | 2015-12-23 | 한국과학기술연구원 | mGluR5의 표식용 방사성 조성물 |
EP3285582B1 (en) | 2015-03-26 | 2020-11-11 | Merck Sharp & Dohme Corp. | Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors |
EP3294705B1 (en) | 2015-05-14 | 2021-07-21 | The Wistar Institute Of Anatomy And Biology | Ebna1 inhibitors and methods using same |
AU2016270903B2 (en) | 2015-06-03 | 2020-04-30 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists for use in the treatment of cardiovascular disorders |
EP3459939A1 (en) * | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Novel heterocyclic compounds as modulators of mglur7 |
TW201946919A (zh) | 2018-05-17 | 2019-12-16 | 威斯塔研究所 | Ebna1抑制劑晶形、其製備方法及其使用方法 |
EP4049661A4 (en) * | 2019-10-21 | 2023-11-08 | SK Biopharmaceuticals Co., Ltd. | USE OF AN IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND TO PREVENT, RELIEF OR TREAT DEVELOPMENTAL DISABILITIES |
US20220370461A1 (en) * | 2019-10-21 | 2022-11-24 | Sk Biopharmaceuticals Co., Ltd. | Use of imidazopyrimidine or imidazotriazine compounds for prevention, alleviation, or treatment of cognitive disorders, or for improving cognitive function |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100818965B1 (ko) * | 2000-10-02 | 2008-04-04 | 얀센 파마슈티카 엔.브이. | 대사자극성 글루타메이트 수용체 길항제 |
TWI301760B (en) * | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
-
2005
- 2005-08-24 WO PCT/GB2005/003285 patent/WO2007023242A1/en active Application Filing
-
2006
- 2006-08-21 TW TW095130667A patent/TWI329635B/zh not_active IP Right Cessation
- 2006-08-24 JP JP2008527513A patent/JP2009506018A/ja active Pending
- 2006-08-24 KR KR1020087004382A patent/KR20080031972A/ko not_active Application Discontinuation
- 2006-08-24 WO PCT/GB2006/003170 patent/WO2007023290A1/en active Application Filing
- 2006-08-24 BR BRPI0615059-4A patent/BRPI0615059A2/pt not_active IP Right Cessation
- 2006-08-24 AR ARP060103692A patent/AR056044A1/es unknown
- 2006-08-24 CN CNA2006800260106A patent/CN101223142A/zh active Pending
- 2006-08-24 MX MX2008001871A patent/MX2008001871A/es active IP Right Grant
- 2006-08-24 EP EP06779201A patent/EP1931635A1/en not_active Withdrawn
- 2006-08-24 CA CA2610873A patent/CA2610873C/en not_active Expired - Fee Related
- 2006-08-24 EA EA200800660A patent/EA200800660A1/ru unknown
- 2006-08-24 AU AU2006283359A patent/AU2006283359B2/en not_active Ceased
-
2007
- 2007-12-06 ZA ZA200710668A patent/ZA200710668B/xx unknown
-
2008
- 2008-02-19 IL IL189617A patent/IL189617A/en not_active IP Right Cessation
- 2008-03-18 NO NO20081428A patent/NO20081428L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20081428L (no) | 2008-03-18 |
CN101223142A (zh) | 2008-07-16 |
JP2009506018A (ja) | 2009-02-12 |
AR056044A1 (es) | 2007-09-12 |
CA2610873C (en) | 2010-08-03 |
EA200800660A1 (ru) | 2008-06-30 |
BRPI0615059A2 (pt) | 2011-04-26 |
TW200728283A (en) | 2007-08-01 |
IL189617A0 (en) | 2008-06-05 |
ZA200710668B (en) | 2009-08-26 |
AU2006283359A1 (en) | 2007-03-01 |
MX2008001871A (es) | 2008-04-09 |
AU2006283359B2 (en) | 2010-05-27 |
CA2610873A1 (en) | 2007-03-01 |
KR20080031972A (ko) | 2008-04-11 |
EP1931635A1 (en) | 2008-06-18 |
TWI329635B (en) | 2010-09-01 |
WO2007023242A1 (en) | 2007-03-01 |
WO2007023290A1 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2610873C (en) | Tetrahydroquinolines and their use as modulators of metabotropic glutamate receptors | |
US20080032998A1 (en) | Pyrazolopyrimidines, a process for their preparation and their use as medicine | |
US20110003820A1 (en) | Pyrazolopyrimidines, a process for their preparation and their use as medicine | |
CA2556653C (en) | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | |
US20120178742A1 (en) | Metabotropic glutamate receptor modulators | |
EP1957475A1 (en) | Chromenones and their use as modulators of metabotropic glutamate receptors | |
US20070299113A1 (en) | Metabotropic glutamate receptor modulators | |
EP1943247A1 (en) | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | |
WO2012085166A1 (en) | Metabotropic glutamate receptor modulators | |
US7550482B2 (en) | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | |
US20060004001A1 (en) | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | |
WO2008035049A1 (en) | Adamantanyl-(cyclopropyl)-ketones as metabotropic glutamate receptor modulators | |
WO2012152854A1 (en) | Metabotropic glutamate receptor modulators | |
MXPA06009564A (es) | Tetrahidroquinolinonas y su uso como antagonistas de receptores de glutamato metabotropico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
MM9K | Patent not in force due to non-payment of renewal fees |